65,437 trials
Metastatic Solid Tumors of Metastatic Disease
Primary: Number of Participants With Skeletal Related Events (SREs) — 10; 1; 29; 38 number of participants
HIV Infection
Primary: Time to Meeting Criteria for ART Re-initiation — 7.9; 8.9; 7.6 Weeks
Head and Neck Squamous Cell Carcinoma
Primary: The Number of Subjects Who Achieve at Least a 30 Percent Decrease in Pain From Baseline in VAS Pain Score Calculated From BPI Questionnaire. — 8 Participants
Chronic Kidney Diseases
Primary: Changes in Intermuscular Fat Deposition as Assessed by Magnetic Resonance Imaging (MRI). — -0.009 fat/muscle ratio
Sickle Cell Disease
Primary: Pain Rating Using Numerical Pain Rating Scale (NPRS) — 3.79; 3.17; 2.37; 2.63 score on a scale
Incomplete Spinal Cord Injury
Primary: Arm and Hand Function as Assessed by Score on the Graded Redefined Assessment of Strength, Sensibility and Prehension (GRASSP) — 64.9; 58.3 score on a scale
Influenza · Respiratory Tract Infections
Primary: Receipt of the Annual Influenza Vaccine Among Index Patients — 3557; 3518; 3479 Participants
Stroke · Stroke Sequelae · Motor Activity
Primary: Safety of Combined taVNS and TMS — 0 Participants
Breast Cancer · Neutropenia
Primary: Duration of Grade 3 or 4 Neutropenia (ANC <1.0×10^9/L) in Cycle 1 — 0.68; 0.71 days
Chronic Pruritus
Primary: Numeric Rating Scale for Itch — 6.42; 7.8 score on a scale (0~10)
Relapsing-remitting Multiple Sclerosis
Primary: Confirmed Disease Progression in Patients With Expanded Disability Status Scale (EDSS) <2.5 at Baseline — 20; 50; 5; 14 Participants
Pelvic Organ Prolapse
Primary: Pain Score at 4 Hours — 3.16; 3.77 score on a scale
BPG Intervention · Control
Primary: Kaufman Assessment Battery for Children 2nd Edition (KABC-II) Mental Processing Index (MPI) — 77.18; 74.79; 71.79; 73.72 units on a scale — p=<.01
Primary Hypercholesterolemia or Mixed Dyslipidemia
Primary: Percentage Change in Low-density Lipoprotein Cholesterol (LDL-C) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part — -45.87; 1.62 % change in LDL-C — p=<0.0001
Alpha 1-Antitrypsin Deficiency
Primary: Percent Change From Baseline in Total Liver Z-AAT, Insoluble Liver-ZAAT, and Soluble Liver Z-AAT at Week 24: Cohorts 1/1b — -83.07; -79.84; -81.58; -12.91 percent change